Avalo Therapeutics, Inc. · NASDAQ:AVTX

T. Rowe Price Investment Management, Inc. reported a 9.50% stake in Avalo Therapeutics, Inc. (Schedule 13G)

Event Mar 31, 2026 · Filed May 15, 2026

T. Rowe Price Investment Management, Inc. reported a 9.50% stake in Avalo Therapeutics, Inc., 2,162,684 shares, as a passive investor on Mar 31, 2026. Filed May 15, 2026 (Schedule 13G).

Stake
9.50%
Shares
2,162,684
Intent
Passive
What changed
Crossed above 5%

The filing in full

HolderStakeShares
T. Rowe Price Investment Management, Inc.9.50%2,162,684

Source

View original at SEC

Related